Lu Hongbo 4
4 · Terns Pharmaceuticals, Inc. · Filed Dec 23, 2022
Insider Transaction Report
Form 4
Lu Hongbo
Director
Transactions
- Purchase
Common Stock
2022-12-23$7.25/sh+758,620$5,499,995→ 4,340,212 total(indirect: See Footnote)
Footnotes (1)
- [F1]The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. As a managing member of Vivo Opportunity, LLC, Hongbo Lu shares voting and dispositive power over the securities held by Vivo Opportunity Fund Holdings, L.P. with four other managing members but disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein.